Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) has been assigned an average recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $9.50.

A number of equities research analysts recently issued reports on QNCX shares. D. Boral Capital reissued a "buy" rating and issued a $12.00 target price on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They issued a "buy" rating and a $9.00 price objective on the stock.

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors have recently added to or reduced their stakes in QNCX. Geode Capital Management LLC grew its position in shares of Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company's stock valued at $263,000 after acquiring an additional 66,170 shares during the period. Scharf Investments LLC acquired a new position in Quince Therapeutics during the fourth quarter worth approximately $170,000. Anfield Capital Management LLC bought a new stake in Quince Therapeutics in the fourth quarter valued at approximately $50,000. Virtu Financial LLC bought a new position in shares of Quince Therapeutics during the 4th quarter worth approximately $55,000. Finally, Northern Trust Corp increased its holdings in shares of Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after acquiring an additional 16,501 shares during the last quarter. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Quince Therapeutics Stock Up 0.7 %

QNCX traded up $0.01 during trading on Tuesday, hitting $1.38. The company had a trading volume of 98,418 shares, compared to its average volume of 242,039. The company has a market capitalization of $60.72 million, a PE ratio of -1.11 and a beta of 0.71. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The firm's 50-day moving average price is $1.51 and its 200 day moving average price is $1.42.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.